A new concept for bisphosphonate therapy: A rationale for the development of monthly oral dosing of ibandronate

Osteoporosis International

Volumn 17, Issue 2, 2006, Pages 159-166

  Reginster, Jean Yves ^a   Felsenberg, Dieter ^b   Cooper, Cyrus ^c   Stakkestad, Jacob A ^d   Miller, Paul D ^e   Kendler, David L ^f   Adami, Silvano ^g   McClung, Michael R ^h   Bolognese, Michael A ⁱ   Civitelli, Roberto ^j   Dumont, Etienne ^k   Bonvoisin, Bernard ^l   Recker, Robert R ^m   Delmas, Pierre D ⁿ  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d CECOR AS   (Norway)

^e University of Colorado Health Sciences Center   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF VERONA   (Italy)

^h OREGON OSTEOPOROSIS CENTER   (United States)

ⁱ Bethesda Health Research   (United States)

^j WASHINGTON UNIVERSITY   (United States)

^k GLAXOSMITHKLINE   (United States)

^l F HOFFMANN LA ROCHE LTD   (Switzerland)

^m CREIGHTON UNIVERSITY   (United States)

ⁿ UNIVERSITÉ LYON 1   (France)

more..

Author keywords

Bisphosphonate; Convenience; Ibandronate; Intermittent; Monthly; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ETIDRONIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBANDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PROTON PUMP INHIBITOR; RALOXIFENE; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D;

CLINICAL TRIAL; DOG; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERANCE; ESOPHAGUS INJURY; FEASIBILITY STUDY; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; LUMBAR SPINE; MONKEY; NONHUMAN; OSTEOMALACIA; PATIENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; VERTEBRA FRACTURE;

ADMINISTRATION, ORAL; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS, PHASE I; DIPHOSPHONATES; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS; RATS; SPINAL FRACTURES;

EID: 30144440302     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-005-1957-6     Document Type: Review

References (69)

1. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA 280:2077-2082
2. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon M, Melton LJ (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001-1005
3. Cumming RG, Nevitt MC, Cummings SR (1997) Epidemiology of hip fractures. Epidemiol Rev 19:244-257
4. Sernbo I, Johnell O (1993) Consequences of a hip fracture: a prospective study over 1 year. Osteoporos Int 3:148-153
5. Beatriz JE, Perry HM (1994) Age-related osteoporosis. Clin Geriatr Med 10:575-577
6. Gold DT, Lyles KW, Shipp KM, Drezner MK (2001) Osteoporosis and its nonskeletal consequences: their impact on treatment decisions. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis, 2nd edn. Academic Press, San Diego, pp 4779-4784
7. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM Hay SM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC (2001) Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action? QJM 94:575-597
8. Johnell O (1997) The socioeconomic burden of fractures: today and in the 21st century. Am J Med 103:20S-26S
9. Cooper C, Campion G, Melton LJ (1992) Hip fractures in the elderly: a worldwide projection. Osteoporos Int 2:285-289
10. Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102:43-49
11. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209-216
12. Hamilton B, McCoy K, Taggert H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259-262
13. Lombas C, Hakim C, Zanchetta JR (2000) Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 15 [Suppl 1]:M406
14. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209-216
15. Eastell R, Garnero P, Vrijens B (2003) Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study (abstract P-297). Calcif Tissue Int 72:408
16. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965-968
17. Caro J, Isak KJ, Huybrechts KF (2003) Clinical and economic impact of adherence to osteoporosis medication (abstract PL6). Osteoporos Int 14 [Suppl 7]:S2-S3
18. Papapoulos SE (2001) Bisphosphonates in the management of postmenopausal osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis, 2nd edn. Academic Press, New York, pp 631-649
19. Mersfelder T Armitstead JA, Ivey MF, Cedars M (1999) A medication use evaluation of alendronate: compliance with administration guidelines. Pharm Pract Manag Q 18:10-58
20. Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296-1310
21. Rizzoli R, Greenspan SL, Bone G, Schnitzer TJ, for the Alendronate Once-Weekly Study Group (2002) Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17:1988-1996
22. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC 2nd, Kaur A, Thompson DE, Yates J, Orloff JJ (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1-12
23. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R (2002)The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103-111
24. Simon JA, Lewiecki M, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter randomized open-label, crossover study. Clin Ther 24:1871-1886
25. Kendler D, Kung AWC, Fuleihan GE, Gonzalez Gonzalez JG, Gaines KA, Verbruggen N, Melton ME (2004) Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48:243-251
26. Recker RR, Gallagher R, Amonkar M, Smith JC, MacCosbe PE (2004) Medication persistence is better with weekly bisphosphonates, but it remains suboptimal (abstract SA407). J Bone Miner Res 19 [Suppl 1]:S172
27. Cramer JA, Amonkar MM, Hebborn A, Suppapanya N (2004) Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women (abstract M434)? J Bone Miner Res 19 [Suppl 1]:S448
28. Bartl R, Goette S, Hadji P, Hammerschmidt T (2005) Persistence and compliance with daily- and weekly-administered bisphosphonates in German women with osteoporosis ECCEO 2005 (Poster P195)
29. Cooper C, Emkey RD, McDonald RH, Hawker G, Bianchi G, Wilson K, Schimmer RC (2003) Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:4609-4615
30. Peter CP, Handt LK, Smith SM (1998) Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci 43:1998-2002
31. Bone HG, Adami S, Rizzoli R, Favus M, Ross PD, Santora A, Prahalada S, Daifotis A, Orloff J, Yates J (2000) Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther 22:15-28
32. Karam SM (1999) Lineage commitment and maturation of epithelial cells in the gut. Front Biosic 4:D286-D298
33. Bauss F, Russell RGG (2004) Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 15:423-433
34. Leu C, Rodan GA, Reszka AA (2003) Relative binding affinities of bisphosphonates for human bone (abstract). J Bone Miner Res 18 [Suppl 2]:S374
35. Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PH, Hamdy NA, Landman JO, McCloskey EV, Netelenbos JC, Pauwels EK, Roos JC, Valentijn RM, Zwinderman AH (2002) Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 17:1057-1064
36. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249
37. Reginster J-Y, Christiansen C, Roux C, Fechtenbaum J, Rouillon A, Tou KP (2001) Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporos Int 12:169-177
38. Mühlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H (1991) BM21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011
39. Bauss F, Mühlbauer RC (1994) BM 21.0955, monosodium salt monohydrate. Drugs Future 19:13-16
40. Green JF (2001) Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol 28 [Suppl 6]:4-10
41. Bauss F (1997) Ibandronate in malignant bone diseases and osteoporosis - preclinical results. Onkologie 20:204-208
42. Delmas PD, Recker RR, Chesnut CH III (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792-798
43. Reginster J-Y (submitted) Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Curr Pharm Des
44. Schimmer RC, Bauss F (2003) Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther 25:19-34
45. World Health Organization (1998) Guidelines for the preclinical evaluation and clinical trials in osteoporosis. WHO, Geneva
46. Bauss F, Lalla S, Endele R, Hothorn (2002a) Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol 29:2200-2208
47. Bauss F, Wagner M, Hothorn LH (2002b) Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J Rheumatol 29:990-998
48. Fleisch H (1996) The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat. Osteoporos Int 6:166-170
49. Lalla S, Hothorn LA, Haag N, Bader R, Bauss F (1998) Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos Int 8:97-103
50. Monier-Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, Boskey AL, Malluche HH (1999) Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 14:1768-1778
51. Smith SY, Recker RR, Hannan M, Müller R, Bauss F (2003) Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32:45-55
52. Müller R, Hannan MK, Smith SY, Bauss F (in press) Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J Bone Miner Res
53. Monier-Faugere MC, Friedler RM, Bauss F, Malluche HH (1993) A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 8:1345-1355
54. Delmas PD, Emkey R, Gilbride J, Schimmer RC, Leishman B, Rosen CJ (2003) Oral ibandronate has a similar gastrointestinal (GI) safety profile to placebo in patients with a history of GI disorders or receiving concomitant NSAIDs (abstract P267). Osteoporos Int 14 [Suppl 7]:S74
55. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC 3rd, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79
56. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 323:1265-1271
57. Reginster J-Y, Wiese C, Wilson K, Schimmer RC (2003) Monthly oral ibandronate decreases bone turnover in postmenopausal women with low bone mass: results from the Monthly Oral Pilot Study (MOPS) (abstract OC15). Osteoporos Int 14 [Suppl 7]:S5
58. Geischke R, Hayashi N, Vis P, Jacqmin P (2003) Modelling the effects of ibandronate treatment on the time course of bone mineral density change in osteoporotic postmenopausal women (abstract P-280). Calcif Tissue Int 72:404
59. Temple RJ (2003) Study designs in osteoporosis. J Bone Miner Res 18:1129-1132
60. World Medical Association (2000) Declaration of Helsinki: ethical principles for medical research involving human subjects. 52nd World Medical Association General Assembly, 3-7 October 2000, Edinburgh, Scotland
61. Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236
62. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592
63. Khosla S (2003) Surrogates for fracture endpoints in clinical trials. J Bone Miner Res 18:1146-1149
64. Wasnich R, Miller PD, Chesnut CH, Huss H, Wilson K, Schimmer RC (2003) Changes in bone mineral density as a predictor for vertebral fracture efficacy with ibandronate: results from a phase III fracture study (abstract SA353). J Bone Miner Res 18 [Suppl 2]:S160
65. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19:394-401
66. Delmas PD, Calvo G, Boers M, Abadie E, Avouac B, Kahan A, Kaufman JM, Laslop A, Lekkerkerker JF, Nilsson P, Van Zwieten-Boot B, Kreutz G, Reginster JY, Group for the Respect of Ethics and Excellence in Science (GREES) (2002) The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int 13:1-5
67. Committee for Proprietary Medicinal Products (CPMP) (2000) Points to consider on switching between superiority and non-inferiority. The European Agency for the Evaluation of Medicinal Products, London
68. Ravn P, Clemmesen B, Riis BJ, Christiansen C (1996) The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1 year, randomised, double-blind, placebo controlled dose finding study. Bone 19:527-533
69. Riis BJ, Ise J, Von Stein T, Bagger Y, Christiansen C (2001) Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 16:1871-1878